Why this East Bay drug maker's stock price nearly doubled last year

A new wrinkle to an old treatment helped an East Bay company nearly double its stock price as it moves toward a regulatory decision on its drug for removing "frown lines" between the eyebrows. While the long-term prospects of Revance Therapeutics Inc. (NASDAQ: RVNC) may rest more with the billion-dollar potential of its drug as a longer-lasting alternative to Botox for erasing facial wrinkles, the company is lining up clinical trials testing its drug as a therapeutic against neck spasms , a common…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news